






Dear all

- Merry Christmas to everyone! 🎅
- Bern (INSEL), Switzerland, has included their first TRAUMOX2 patient. Congratulations! We are officially recruiting in three countries now.
- We have also passed the 50% recruitment mark in the study. A huge thanks to everyone involved.



Focus point

We are closing in on the 2nd interim analysis. Therefore, 30-day mortality and major lung complications should be assessed on as many eligible patients as possible the next month.

With best regards

Jacob Steinmetz (sponsor)

&

Tobias Arleth (c. investigator)